First slide

Russia’s sovereign wealth fund the Russian Direct Investment Fund (RDIF), and India’s leading generic pharmaceutical company Hetero agreed to produce over 100 million doses of Sputnik V vaccine in India.

  • Sputnik V vaccine is the world’s first registered vaccine against the novel coronavirus infection.
  • The parties intend to start the production of Sputnik V in the beginning of 2021.
    • Currently Phase III clinical trials are approved and are ongoing in Belarus, the UAE, Venezuela and other countries, as well as Phase II-III in India.

    The recent investments and deals by RDIF in last three months are featured below:

    Sep 2020: Russian Direct Investment Fund (RDIF) and the leading pharma company of India, Dr. Reddy’s Laboratories Ltd. has agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India.

    Aug 2020: Russian Direct Investment Fund (RDIF) and leading Kazakh company SK-Pharmacy, have announced an agreement for the supply of the Russian Sputnik V vaccine to Kazakhstan.

    July 2020: The Russian Direct Investment Fund (RDIF), and ChemRar Group joint venture Chromis announced the the signing of collaboration agreement with Brazil’s Axis BioTec to deliver the first Russian anti-COVID drug Avifavir to Brazil.

    July 2020: Russian agency the Russian Direct Investment Fund (RDIF) and ChemRar Group announced the production of first 100,000 courses of the Russian coronavirus drug Avifavir, and significantly exceeding initially planned production levels of 60,000 courses.

    June 2020: Russia’s sovereign wealth funds the Russian Direct Investment Fund (RDIF) announce a partnership with R-Pharm Group as part of joint efforts to combat coronavirus infection and produce the first Russian vaccine with high export potential.

    June 2020: Russia’s investment agency Russian Direct Investment Fund (RDIF), announces a strategic partnership between its portfolio company Doctis and Mail.ru Group, Russia’s leading internet and IT-company.

    May 2020: RDIF announced that Russia-Japan Investment Fund (RJIF), joins the investment in the Russia-Japan coronavirus diagnostics system EMG – Evotech Mirai Genomics. EMG is one of the world’s fastest and most accurate systems and able to detect the virus in few minutes.

    April 2020: The Russian Direct Investment Fund (RDIF), announced the production of a first batch of 200 litres of cell culture fluid biomass in partnership with the Russian-Japanese company EMG. This will enable EMG to produce up to one million high-quality rapid tests for the detection of COVID-19.

    March 2020, The Russian Direct Investment Fund (RDIF), announced its supports to MD Medical Group (RDIF portfolio company) to start treating patients with pneumonia symptoms, including patients with coronavirus symptoms, at its clinical hospital Lapino.

    March 2020, The Russian Direct Investment Fund (RDIF), RUIE (the Russian Union of Industrialists and Entrepreneurs), Yandex and Mail.ru Group announced the creation of an alliance against coronavirus (COVID-19).

About RDIF
Moscow based Russian Direct Investment Fund (RDIF) is Russia’s sovereign wealth fund. RDIF was founded in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. It has implemented almost 70 projects in partnership with foreign entity. RDIF’s portfolio of companies employs approximately 800,000 people and generates revenues which equate to over 6% of Russia’s GDP.

Related News